Modern biopharmaceuticals [[electronic resource] ] : recent success stories / / edited by Jorg Knablein

• Pubblicazione: Weinheim ; ; Chichester, : Wiley-VCH, 2013
• Descrizione fisica: 1 online resource (778 p.)
• Disciplina: 615.19
• Soggetto topico: Biopharmaceutics; Drugs - Testing - Research
• Altri autori: KnableinJorg
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Modern Biopharmaceuticals: Recent Success Stories; Contents; Foreword by Andreas Busch; Foreword by Günter Stock; Preface; Quotes; List of Contributors; Part I: Modern Biopharmaceuticals: Research is the Best Medicine - Sanitas Summum Bonus; 1 Twenty Thousand Years of Biotech - From "Traditional" to "Modern Biotechnology"; 1.1 Biotechnology - The Science Creating Life; 1.2 The Inauguration of Biotechnology; 1.3 From "Traditional" to "Modern Biotechnology"; 1.3.1 Molecular Genetics and Enzymatic Kinetics; 1.3.2 Penicillin and Other Lifesaving Antibiotics ; 1.3.3 The Triumphal Procession of Vitamin C1.4 A Small Molecule from Bacteria - A Huge Importance for Mankind; 1.4.1 Plasmids: Transformation by Gene Transfer; 1.4.2 DNA: The Molecule of Life; 1.4.3 Immortalized Cells: The Source of Monoclonal Antibodies; 1.4.4 Insulin: The First Biotech Blockbuster; 1.4.5 Polymerase Chain Reaction: How to Infinitely Amplify DNA; 1.5 Biopharmaceuticals - The Mainstay of Modern Biotechnology; 1.5.1 Modern Biopharmaceuticals in Europe; 1.6 Transformation of the Pharma Industry Through Biotechnology; 1.6.1 The Market as Motivation for Transformation ; 1.6.2 Innovations and Where They do Come From1.6.3 Mergers and Acquisitions in the Biopharmaceutical Industry and the Impact on Innovation; 1.6.4 A Focus on the Opportunities of European Biotech Industry; 1.7 Biopharmaceutical Production - Uncorking Bottlenecks or Wasting Surplus Capacity?; 1.8 Conclusion and Outlook; References; Part II: Modern Biopharmaceutical Development Using Stem Cells, Tissues, and Whole Animals; 2 Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? - The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals ; 2.1 Introduction2.2 Derivation and Growth of hESC; 2.3 Signaling Pathways and Transcription Factors; 2.4 Differentiation and Applications of hESC; 2.5 Patient-Specific Nuclear Transfer Stem Cells; 2.6 Patient-Specific Pluripotent Cells Through Direct Reprogramming of Adult Somatic Cells; 2.7 Concluding Remarks and Outlook; References; 3 Pluripotent Stem Cell-Derived Cardiomyocytes for Industrial and Clinical Applications; 3.1 Introduction; 3.2 Pluripotent Stem Cells; 3.2.1 Embryonic Stem Cells; 3.2.2 Parthenogenetic Stem Cells; 3.2.3 Germline Pluripotent Stem Cells ; 3.2.4 Induced Pluripotent Stem Cells3.3 High-Yield Differentiation of Pluripotent Stem Cells into Cardiomyocytes; 3.4 Purification of Pluripotent Stem Cell-Derived Cardiomyocytes; 3.5 Cardiomyocytes at an Industrial Scale; 3.6 Utilization of Tissue Engineering Technologies to Advance Cellular Maturity; 3.7 Concluding Remarks; References; 4 Industrialization of Functional Mouse Genomics Technologies for Biopharmaceutical Drug Discovery and Development; 4.1 Introduction; 4.2 The Mouse Genetics Story; 4.3 Establishing Inducible Gene Targeting Tools; 4.4 RNAi - Talking About a Revolution? ; 4.5 Further Shortening the Generation Timeline for RNAi Mouse Models
• Sommario/riassunto: This collection of high-profile contributions provides a unique insight into the development of novel, successful biopharmaceuticals. Outstanding authors, including Nobel laureate Robert Huber as well as prominent company researchers and CEOs, present valuable insider knowledge, limiting their scope to those procedures and developments with proven potential for the biotechnology industry. They cover all relevant aspects, from the establishment of biotechnology parks, the development of successful compounds and the implementation of efficient manufacturing processes, right up to the establish
• Titolo autorizzato: Modern biopharmaceuticals
• ISBN: 3-527-66943-4; 3-527-66941-8; 1-299-44890-9; 3-527-66942-6
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910139022003321
• Lo trovi qui: Univ. Federico II